Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.

ABSTRACT:

Background

Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist that is used to treat moderate to severe Alzheimer's Dementia (AD) and has been speculated to provide clinical benefits in Huntington's disease (HD).

Objective

To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.

Methods

Using participants from the Enroll-HD study, the primary analysis compared trajectories in cognition over a 5-year period using linear mixed effect models of prevalent and incident memantine users who were propensity-score-matched with non-users on measures of disease progression and demographics.

Results

In the primary analysis there were no significant differences in the trajectories between mema

SUBMITTER: Ogilvie AC 

PROVIDER: S-EPMC10354618 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature